1. 1. Sotomi Y, Suwannasom P, Serruys PW, Onuma Y. Possible mechanical causes of scaffold thrombosis: Insights from case reports with intracoronary imaging. EuroIntervention 2017; 12: 1747–1756.
2. 2. Chamie D, Garcia-Garcia H, Costa RA, Onuma Y, Abizaid A, Serruys PW. Role of invasive imaging in acute and long-term assessment of bioresorbable scaffold technology. Catheter Cardiovasc Interv 2016; 88: 38–53.
3. 3. Onuma Y, Sotomi Y, Shiomi H, Ozaki Y, Namiki A, Yasuda S, et al. Two-year clinical, angiographic, and serial optical coherence tomographic follow-up after implantation of an everolimus-eluting bioresorbable scaffold and an everolimus-eluting metallic stent: Insights from the randomised ABSORB Japan trial. EuroIntervention 2016; 12: 1090–1101.
4. 4. Chevalier B, Onuma Y, van Boven AJ, Piek JJ, Sabaté M, Helqvist S, et al. Randomised comparison of a bioresorbable everolimus-eluting scaffold with a metallic everolimus-eluting stent for ischaemic heart disease caused by de novo native coronary artery lesions: The 2-year clinical outcomes of the ABSORB II trial. EuroIntervention 2016; 12: 1102–1107.
5. 5. Raber L, Brugaletta S, Yamaji K, O’Sullivan CJ, Otsuki S, Koppara T, et al. Very late scaffold thrombosis: Intracoronary imaging and histopathological and spectroscopic findings. J Am Coll Cardiol 2015; 66: 1901–1914.